<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119405</url>
  </required_header>
  <id_info>
    <org_study_id>1R01AI060484-01A2A</org_study_id>
    <secondary_id>1R01-AI060484-01A2A</secondary_id>
    <secondary_id>1R01AI060484-01A2</secondary_id>
    <nct_id>NCT00119405</nct_id>
  </id_info>
  <brief_title>Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</brief_title>
  <official_title>Role of Mitochondria in the Development of HIV Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nucleoside reverse transcriptase inhibitors (NRTIs) are a class of anti-HIV (Human
      Immunodeficiency Virus) drug that can be an important part of an HIV treatment regimen.
      Because anti-HIV therapy may have negative side effects, there is a great need to carefully
      study HIV infected patients on such regimens. One negative side effect observed in many HIV
      infected patients is lipoatrophy, a condition that results in fat loss in the body. It is
      unclear if NRTIs also have a role in the development of mitochondrial toxicity, a condition
      that affects the body's ability to produce energy. The purpose of this study is to observe
      the effects of an NRTI-based, protease inhibitor (PI)-sparing drug regimen on fat loss in HIV
      infected, treatment-naive adults.

      Study hypothesis: The initiation of NRTI-containing, PI-sparing therapy will inhibit
      mitochondrial DNA (mtDNA) synthesis and lead to a decrease in mtDNA content in adipose
      tissue, skeletal muscle and peripheral blood mononuclear cells (PBMCs), will cause
      deterioration in mitochondrial function, will increase fat apoptosis and oxidative damage
      biomarkers, and will lead to progressive decrease in body fat content.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NRTIs are a mainstay of HIV treatment regimens, often part of initial treatment regimens for
      newly diagnosed patients. Recent data suggest that NRTIs are responsible for lipoatrophy, a
      condition marked by progressive fat loss. Another negative side effect to antiretroviral
      (ARV) regimens is mitochondrial toxicity, which can damage the heart, nerves, muscles,
      kidneys, pancreas and liver, as well as affecting the body's ability to produce energy for
      important life processes. It has been hypothesized that lipoatrophy may be related to
      mitochondrial toxicity, but a causal relationship between the two has yet to be established.
      This study will examine HIV infected treatment-naive patients who are initiating their first
      ARV regimens. The regimens will contain 2 NRTI, one of which being zidovudine and a
      non-nucleoside reverse transcriptase inhibitor (NNRTI). The regimens will not contain any
      PIs.

      Patients will participate in this study for 96 weeks. There will be 4 study visits at Weeks
      12, 24, 48, and 96. Dual-energy x-ray absorptiometry (DEXA) scans and fat biopsies will occur
      at all visits. Additionally, blood collection for metabolic testing will occur at Week 12.
      ARVs will not be provided by this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mitochondrial Function (mtDNA Levels)</measure>
    <time_frame>96 weeks</time_frame>
    <description>Mitochondrial gene expression: mtDNA levels are used to quantify this outcome measure.</description>
  </primary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>HIV Infections</condition>
  <condition>Lipodystrophy</condition>
  <condition>Metabolic Diseases</condition>
  <condition>Nutrition Disorders</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fat and Blood for mitochindrial DNA and different nuclear genes that regulate fat and lipid
      metabolism
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV positive adults starting their first antiretroviral regimen with either azidothymidine
        (AZT)-containing combination
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected

          -  Treatment-naive

          -  Plan to initiate first ARV regimen with 2 NRTIs and an NNRTI

          -  Plan to include zidovudine as part of first ARV regimen

        Exclusion Criteria:

          -  Current use of steroids or growth hormone

          -  Coagulopathies or other bleeding disorders

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace A. McComsey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2005</study_first_submitted>
  <study_first_submitted_qc>July 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2005</study_first_posted>
  <results_first_submitted>June 13, 2016</results_first_submitted>
  <results_first_submitted_qc>February 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2017</results_first_posted>
  <last_update_submitted>February 10, 2017</last_update_submitted>
  <last_update_submitted_qc>February 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lipoatrophy</keyword>
  <keyword>Mitochondria</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred from 6/2005 to 11/2008. Participants were recruited from 3 HIV clinics in Cleveland, with the majority from the clinic at University Hospitals Case Medical Center.</recruitment_details>
      <pre_assignment_details>Participants had to be HIV+ and naive to ARVs.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ARV Naive</title>
          <description>ARV naive</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ARV Naive</title>
          <description>ARV naive</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.88" spread="8.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mitochondrial Function (mtDNA Levels)</title>
        <description>Mitochondrial gene expression: mtDNA levels are used to quantify this outcome measure.</description>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARV Naive</title>
            <description>ARV naive (have never been on antiretrovirals before)</description>
          </group>
        </group_list>
        <measure>
          <title>Mitochondrial Function (mtDNA Levels)</title>
          <description>Mitochondrial gene expression: mtDNA levels are used to quantify this outcome measure.</description>
          <units>copies per cell</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1372" lower_limit="532" upper_limit="2721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ARV Naive</title>
          <description>ARV naive (have never been on antiretrovirals before)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis (Grade 3)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia (Grade 2)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Right Lower Lobe (RLL) Pneumonia (Grade 3)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Low absolute neutrophil count (ANC) (Grades 2 and 3)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Low white blood cell (WBC) count (Grade 2)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia (Grade 2)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Aspartate aminotransferase (AST) (Grades 2 and 3)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Elevated alanine aminotransferase (ALT) 207 (Grade 2)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Low glucose 34 (Grade 3)</sub_title>
                <description>Lab delay - repeated result was 105</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Low glucose 48 (Grade 2)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Elevated Cholesterol 257 (Grade 2)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Elevated low-density lipoprotein (LDL) 175 (Grade 2)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Mineral Density (BMD)/T scores -2.3 and -3.2</sub_title>
                <description>Known osteoporosis pre-study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Elevated creatine kinase (CK) levels (Grades 3 and 4)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Incisional Seroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Incisional Hematoma (Grade 1)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infected Incisional Hematoma (Grade 2)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Grace McComsey</name_or_title>
      <organization>Case Western Reserve University</organization>
      <phone>216-844-3607</phone>
      <email>mccomsey.grace@clevelandactu.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

